HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis

Cellular Physiology and Biochemistry

Volumn 34, Issue 1, 2014, Pages 172-184

  Sattler, Katherine ^a   Lehmann, Isa ^a   Gräler, Markus ^b   Bröcker Preuss, Martina ^a   Erbel, Raimund ^a   Heusch, Gerd ^a   Levkau, Bodo ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

High density lipoproteins (HDL); Multi vessel disease; Restenosis; Sphingosine 1 phosphate (S1P); Stable coronary artery disease (CAD); Stenosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOSINE 1 PHOSPHATE; LYSOPHOSPHOLIPID; PROTEIN BINDING; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RESTENOSIS; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; STENOSIS, OCCLUSION AND OBSTRUCTION; BLOOD SAMPLING; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ELECTIVE SURGERY; LIPOPROTEIN BLOOD LEVEL; QUANTITATIVE STUDY;

AGED; AREA UNDER CURVE; CONSTRICTION, PATHOLOGIC; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BINDING; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPHINGOSINE;

EID: 84904017755     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000362993     Document Type: Article

References (27)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714. (Pubitemid 8110784)
3. Rahilly-Tierney C, Sesso HD, Michael Gaziano J, Djousse L: High-density lipoprotein and mortality before age 90 in male physicians. Circ Cardiovasc Qual Outcomes 2012;5:381-386.
4. Assmann G, Gotto AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109:SIII8-14.
5. Besler C, Luscher TF, Landmesser U: Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012;4:251-268.
6. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B: High-density lipoproteins and their constituent, sphingosine-1- phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114:1403-1409. (Pubitemid 44454560)
7. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-581. (Pubitemid 38542506)
8. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F: Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001;276:31780-31785.
9. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM, Argraves WS: High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 2008;283:25074-25081.
10. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR: HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008;28:1542-1548.
11. Gonzalez-Diez M, Rodriguez C, Badimon L, Martinez-Gonzalez J: Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost 2008;100:119-126. (Pubitemid 351948753)
12. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, Brocker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B: Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010;105:821-832.
13. Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N, Sabbadini RA: Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003;146:62-68. (Pubitemid 36851301)
14. Mauri L, Orav EJ, Kuntz RE: Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111:3435-3442. (Pubitemid 40923397)
15. Egom EE, Mamas MA, Chacko S, Stringer SE, Charlton-Menys V, El-Omar M, Chirico D, Clarke B, Neyses L, Cruickshank JK, Lei M, Fath-Ordoubadi F: Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol 2013;4:130.
16. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE: Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006;47:992-997.
17. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-1682. (Pubitemid 46631626)
18. Krause BR, Remaley AT: Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol 2013;24:480-486.
19. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-374. (Pubitemid 44394906)
20. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA: High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 2014;114:205-213.
21. Sattler K, Levkau B: Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009;82:201-211.
22. Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, Cholez G, Keyserling C, Lalwani N, Paolini JF, Dasseux JL, Barbaras R, Baron R: CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014;232:110-118.
23. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B: High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001;103:3047-3050. (Pubitemid 32587849)
24. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B: Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998;97:780-785. (Pubitemid 28135341)
25. Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974-980. (Pubitemid 34633863)
26. Kones R: Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag 2010;6:635-656.
27. Knapp M, Lisowska A, Zabielski P, Musial W, Baranowski M: Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat 2013;106:53-61.